Tonix is developing innovative pharmaceutical products to address major public health challenges. In addition to Tonmya for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage, designed as a daytime treatment for PTSD, and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine.

Pharmaceutical

Tonix Pharmaceuticals

Seth Lederman

Gary Brune

Ram Patalapati

Jean Engels

Scott Szymanski

Sina Bavari

Darryl Rideout

Bradley Saenger

Jessica Edgar Morris

Gregory Sullivan

Siobhan Fogarty

Leadership Team

Research and Development

Clinical Operations Team

Quality Control and Assurance

Teams at Tonix Pharmaceuticals

Leadership Team

Research and Development

Clinical Operations Team

Quality Control and Assurance